A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > BUSINESS
BUSINESS
- US FDA Accepts Filing for Astellas Pharma’s Mirabegron
November 11, 2011
- Nipro: Net Profits Down 81.5% due to Great East Japan Earthquake
November 11, 2011
- Fuso’s Ordinary and Net Losses were Pushed into Deficit by Quake (April-September 2011)
November 10, 2011
- Asahi Kasei Pharma to Accelerate Coagulant Development, Makes US Venture Wholly-Owned Subsidiary
November 10, 2011
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
- Nippon Shinyaku Increases Both Sales, Profits Driven by Growth of Vidaza
November 10, 2011
- Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan
November 10, 2011
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
- Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
- Yakult, LivTech Enter into Option Agreement for Anti-Cancer Monoclonal Antibody Development Program
November 9, 2011
- Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
- Nihon Chouzai Planning to Open 150-200 Stores a Year: President Mitsuhara
November 9, 2011
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
- Nichi-Iko to Change Company Structure to Strengthen Sales of Generic Drugs
November 8, 2011
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…